On October 8, ASYMCHEM fell 3.02% in regular trading, trading at HK$160.50 with turnover of HK$69.6041 million.

The decline comes amid continued institutional selling pressure. JPMorgan reduced its long position by 83,200 shares on September 23 at an average price of HK$159.1287 per share, lowering its stake to 8.8%. Schroders PLC also cut 175,800 shares on September 24 at approximately HK$150.23 per share. The consecutive institutional reductions have dampened market sentiment. Although the company's fundamentals remain solid, including an order backlog of US$1.673 billion up 53.77% year-over-year and its chemical macromolecule site passing FDA pre-approval inspection, the combination of pre-holiday risk aversion and foreign capital rebalancing pressure continues to weigh on the stock.

ASYMCHEM is a China-based company providing one-stop pharmaceutical outsourcing services, including small molecule CDMO, chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output, and synthetic biology.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)